Vienna, Austria — 26 June 2024 — IAMA Therapeutics is in the spotlight this week at the FENS Forum 2024 (#FENS2024), Europe’s largest neuroscience meeting, taking place 25–29 June at the Messe Wien Exhibition & Congress Center. Yesterday, 25 June, our Founder Laura Cancedda, PhD (Istituto Italiano di Tecnologia) presented cutting‑edge data on chloride‑transport modulation emerging from her lab, outlining how these discoveries lay the groundwork for next‑generation therapies in neurodevelopmental disorders.
Today, 26 June, Annalisa Savardi, PhD, Head of Neuropharmacology, unveiled the full pre‑clinical package of our lead compound IAMA‑6 during a packed poster session. The data highlight IAMA‑6’s selective NKCC1 inhibition, favorable brain penetration, and robust efficacy across multiple in‑vivo models.
